A review of HSV pathogenesis, vaccine development, and advanced applications

Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)

Published: Aug. 29, 2024

Herpes simplex virus (HSV), an epidemic human pathogen threatening global public health, gains notoriety for its complex pathogenesis that encompasses lytic infection of mucosal cells, latent within neurons, and periodic reactivation. This intricate interplay, coupled with HSV's sophisticated immune evasion strategies, gives rise to various diseases, including genital lesions, neonatal encephalitis, cancer. Despite more than 70 years relentless research, effective preventive or therapeutic vaccine against HSV has yet emerge, primarily due the limited understanding virus-host interactions, which in turn impedes identification targets. However, unique pathological features, substantial genetic load capacity, high replicability, transmissibility, neurotropism, render it a promising candidate applications, spanning oncolytic virotherapy, gene therapies, even as imaging tracer neuroscience. In this review, we comprehensively update recent breakthroughs evasion, critically summarize progress made development, discuss multifaceted applications biological tool. Importantly, highlight both success challenges, emphasizing critical need intensified research into HSV, aim providing deeper insights can not only advance treatment strategies but also broaden application horizons.

Language: Английский

---

Quality‐of‐Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient‐Oriented Outcomes and External Experts

International Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

In this paper, the European Academy of Dermatology and Venereology (EADV) Task Force on Quality Life (QoL) Patient-Oriented Outcomes presents its position statements health-related (HR) QoL assessment in epidermolysis bullosa (EB). The EADV TF recommends use EB-specific instrument QOLEB patients over age 10 years and, addition to QOLEB, iscorEB-p moderate-to-severe EB; IntoDermQoL proxy with module should be used children aged under 5 years. iscorEB-p, dermatology-specific CDLQI may measure HRQoL EB from Dermatology-specific and/or generic instruments compare impact other diseases; family studied using EB-BoD, measures, instruments.

Language: Английский

---

Nanotheranostics Revolutionizing Gene Therapy: Emerging Applications in Gene Delivery Enhancement

Journal of Nanotheranostics, Journal Year: 2025, Volume and Issue: 6(2), P. 10 - 10

Published: April 9, 2025

Nanotheranostics—where nanoscale materials serve both diagnostic and therapeutic functions—are rapidly transforming gene therapy by tackling critical delivery challenges. This review explores the design engineering of various nanoparticle systems (lipid-based, polymeric, inorganic, hybrid) to enhance stability, targeting, endosomal escape genetic payloads. We discuss how real-time imaging capabilities integrated into these platforms enable precise localization controlled release genes, improving treatment efficacy while reducing off-target effects. Key strategies overcome barriers (such as proton sponge effect photothermal disruption) achieve nuclear are highlighted, along with recent advances in stimuli-responsive that facilitate spatiotemporal control expression. Clinical trials preclinical studies demonstrate expanding role nanotheranostics managing cancer, inherited disorders, cardiovascular neurological diseases. further address regulatory manufacturing hurdles must be for widespread clinical adoption nanoparticle-based therapies. By synthesizing progress ongoing challenges, this underscores transformative potential effective, targeted, image-guided delivery.

Language: Английский

---

Epidermolysis bullosa for primary care providers: A practical review

Journal of General and Family Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

Abstract Epidermolysis bullosa (EB) is a group of genetic skin diseases, which manifest as fragile and blistering in addition to many extracutaneous conditions. Pediatricians primary care providers play an integral role managing these patients with multifaceted needs. There are resources navigate treating the various manifestations EB assist partnership between pediatricians, dermatologists, other specialists. also newly approved therapies for some forms EB. As may only attend multidisciplinary clinic management their condition at designated intervals, provider becomes first point contact acute or healthcare maintenance visits. Using tips discussed herein, pediatrician can work rest medical team best optimize clinical outcomes

Language: Английский

---